Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 11
1998 8
1999 33
2000 28
2001 22
2002 34
2003 41
2004 35
2005 35
2006 38
2007 22
2008 26
2009 37
2010 21
2011 25
2012 26
2013 25
2014 28
2015 20
2016 20
2017 18
2018 14
2019 24
2020 20
2021 15
2022 18
2023 13
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier P, Roche N, Faisy C. Devillier P, et al. Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001. Clin Pharmacokinet. 2008. PMID: 18336052 Review.
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levocetirizine - many pharmacological and clinical criteria must be considered. ...Desloratadine and fexofenadine do not impair cognitive …
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levo …
Allergic Rhinitis: A Review.
Bernstein JA, Bernstein JS, Makol R, Ward S. Bernstein JA, et al. JAMA. 2024 Mar 12;331(10):866-877. doi: 10.1001/jama.2024.0530. JAMA. 2024. PMID: 38470381 Review.
In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamine (eg, cetirizine, fexofenadine, desloratadine, loratadine) or an intranasal antihistamine (eg, azelastine, olopatadine), whereas pat …
In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamin …
Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.
Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Kawauchi H, et al. Int J Mol Sci. 2019 Jan 8;20(1):213. doi: 10.3390/ijms20010213. Int J Mol Sci. 2019. PMID: 30626077 Free PMC article. Review.
Antihistamines are classified into non-sedating (<20%), less-sedating (20-50%), and sedating (50%) groups based on H1RO. Among the non-sedating group, fexofenadine and bilastine are classified into "non-brain-penetrating antihistamines" based on the H1RO. ...
Antihistamines are classified into non-sedating (<20%), less-sedating (20-50%), and sedating (50%) groups based on H1RO. Among the non-se …
Fexofenadine.
Markham A, Wagstaff AJ. Markham A, et al. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. doi: 10.2165/00003495-199855020-00012. Drugs. 1998. PMID: 9506246 Review.
The nonsedating histamine H1 receptor antagonist fexofenadine is the active metabolite of terfenadine. It reduced the allergic response in animal models of allergy and did not prolong the QT interval (QTc) in dogs or rabbits at plasma concentrations many times higher than …
The nonsedating histamine H1 receptor antagonist fexofenadine is the active metabolite of terfenadine. It reduced the allergic respon …
Fexofenadine.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1996 Oct 25;38(986):95-6. Med Lett Drugs Ther. 1996. PMID: 8906132 No abstract available.
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in montel

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

Clinical pharmacokinetics of fexofenadine enantiomers.
Miura M, Uno T. Miura M, et al. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Expert Opin Drug Metab Toxicol. 2010. PMID: 19947891 Review.
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers. ...T …
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports t …
[Determinants of the stereoselective pharmacokinetics of fexofenadine].
Akamine Y. Akamine Y. Yakugaku Zasshi. 2015;135(3):473-81. doi: 10.1248/yakushi.14-00218. Yakugaku Zasshi. 2015. PMID: 25759055 Free article. Review. Japanese.
This review focuses on the drug transporters contributing to the stereoselective pharmacokinetics of fexofenadine enantiomers in humans. Fexofenadine is administered clinically as a racemic mixture, and the plasma concentration of (R)-fexofenadine is about 1. …
This review focuses on the drug transporters contributing to the stereoselective pharmacokinetics of fexofenadine enantiomers in huma …
Cardiovascular safety of fexofenadine HCl.
Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R. Pratt CM, et al. Am J Cardiol. 1999 May 15;83(10):1451-4. doi: 10.1016/s0002-9149(99)00124-1. Am J Cardiol. 1999. PMID: 10335761 Review.
Outliers were defined as QTc > 440 ms with a > or = 10 ms increase from baseline. The recommended fexofenadine HCl dose is 60 mg twice daily. Fexofenadine HCl doses up to 800 mg once daily or 690 mg twice daily for 28 days resulted in no dose-related increases …
Outliers were defined as QTc > 440 ms with a > or = 10 ms increase from baseline. The recommended fexofenadine HCl dose is 60 m …
618 results